IL309037A - Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors - Google Patents

Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors

Info

Publication number
IL309037A
IL309037A IL309037A IL30903723A IL309037A IL 309037 A IL309037 A IL 309037A IL 309037 A IL309037 A IL 309037A IL 30903723 A IL30903723 A IL 30903723A IL 309037 A IL309037 A IL 309037A
Authority
IL
Israel
Prior art keywords
cancer
compound
tumor
lymphoma
cell
Prior art date
Application number
IL309037A
Other languages
English (en)
Hebrew (he)
Inventor
Oren Gilad
Joseph VACCA
Eric Brown
Tina Gill
Steve Rocca
Original Assignee
Aprea Therapeutics Inc
Oren Gilad
Joseph VACCA
Eric Brown
Tina Gill
Steve Rocca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea Therapeutics Inc, Oren Gilad, Joseph VACCA, Eric Brown, Tina Gill, Steve Rocca filed Critical Aprea Therapeutics Inc
Publication of IL309037A publication Critical patent/IL309037A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL309037A 2021-06-04 2022-06-03 Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors IL309037A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (1)

Publication Number Publication Date
IL309037A true IL309037A (en) 2024-02-01

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309037A IL309037A (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors

Country Status (10)

Country Link
US (1) US20240254123A1 (https=)
EP (1) EP4347592A1 (https=)
JP (1) JP2024522304A (https=)
KR (1) KR20240044409A (https=)
CN (1) CN117794932A (https=)
AU (2) AU2022287033B2 (https=)
CA (1) CA3225152A1 (https=)
IL (1) IL309037A (https=)
MX (1) MX2023014466A (https=)
WO (1) WO2022256680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CA3071405A1 (en) * 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
KR20240044409A (ko) 2024-04-04
AU2022287033A1 (en) 2024-01-18
AU2022287033B2 (en) 2025-04-17
CN117794932A (zh) 2024-03-29
WO2022256680A1 (en) 2022-12-08
US20240254123A1 (en) 2024-08-01
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10
JP2024522304A (ja) 2024-06-13

Similar Documents

Publication Publication Date Title
IL309037A (en) Pyridopyrimidine derivatives are useful as WEE1 kinase inhibitors
ES2537352T3 (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN116194438A (zh) Ikaros或Aiolos介导的病症的有利疗法
JP2014533699A5 (https=)
ES2822654T3 (es) Benzimidazol-2-aminas como inhibidores de mIDH1
JP2017517548A5 (https=)
EA035658B1 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
JP2020510032A5 (https=)
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
RU2010133979A (ru) Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов
JP2018534289A5 (https=)
ES3032458T3 (en) Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
CN118986981A (zh) 用于治疗或预防癌症的喹啉衍生物
JPWO2023025307A5 (https=)
CN118785912A (zh) 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用
JPWO2022256680A5 (https=)
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途
JPWO2020095256A5 (https=)
EP3973963A1 (en) Quinoline derivatives for treatment of head and neck cancer
EP3028696B1 (en) Agent for alleviating side effects in cancer chemotherapy
EP4134098A1 (en) Method of cancer therapy
JP5409613B2 (ja) 抗腫瘍剤、キット及び癌治療方法
IL316268A (en) ATR inhibitors
US20250289806A1 (en) Compounds for proliferative disorders